Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker 'OTC BB: TYNP'
March 11 2008 - 8:30AM
PR Newswire (US)
CHENGDU, China, March 11 /Xinhua-PRNewswire-FirstCall/ -- Viscorp
Inc. (OTC Bulletin Board: VSCO; TYNP), a manufacturer and supplier
of modernized traditional Chinese medicine ("TCM") based in
Chengdu, China, today announced that it has changed its name to
Tianyin Pharmaceutical, Co., Inc. The corporate name change is
effective immediately. In addition, effective March 11, 2008, the
Company will trade under a new symbol TYNP with the new CUSIP
Number of 88630M 104. Viscorp and Raygere Ltd, which conducts its
business through Chengdu Tianyin Pharmaceutical Co., LTD.
("Tianyin"), jointly announced on January 16, 2008, that the
companies completed a Definitive Share Exchange Agreement whereby
Viscorp acquired all of the outstanding and issued shares of
Tianyin. About Tianyin Pharmaceuticals Tianyin is a manufacturer
and supplier of modernized Traditional Chinese Medicine ("TCM") in
China. It was established in 1994 and acquired by the current
management team in August 2003. It has a comprehensive product
portfolio of 34 modernized TCMs in the market, 22 of which are
listed in the highly selective National Medicine Catalog of the
National Medical Insurance Program. Tianyin owns and operates two
GMP manufacturing facilities and an R&D platform supported by
leading Chinese academic institutions. The Company has a pipeline
of 51 pharmaceutical products pending approval. Tianyin has an
extensive nationwide distribution network throughout China with a
sales force of 523 salespeople. Tianyin is headquartered in
Chengdu, Sichuan Province with two manufacturing facilities and a
total of 869 employees. Tianyin achieved revenue of $20.4 million
and net income of $3.95 million in FY2007 ending June 30, 2007.
Safe Harbor Statement The Statements which are not historical facts
contained in this press release are forward-looking statements that
involve certain risks and uncertainties including but not limited
to risks associated with the uncertainty of future financial
results, additional financing requirements, development of new
products, government approval processes, the impact of competitive
products or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed in the Company's
filings with the Securities and Exchange Commission. For more
information, please contact: For the Company: Allen Tang, Ph.D.,
MBA, Assistant to the CEO Tel: +86-158-2122-5642 Email: Investors:
HC International Alan Sheinwald Tel: +1-914-669-0222 Email:
DATASOURCE: Tianyin Pharmaceutical, Co., Inc. CONTACT: Allen Tang,
Ph.D., MBA, Assistant to the CEO at +86-158-2122-5642 or ; for
investors contact Alan Sheinwald for HC International at
+1-914-669-0222 or
Copyright